T cell-based Immunotherapies
for Cancer and Infectious Diseases
Our Company
Virion is a clinical-stage biopharmaceutical company
Virion Therapeutics is a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize proprietary checkpoint modifiers to restore, enhance, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases. Virion’s lead VRON-0200 Chronic HBV program has now completed a Phase 1b trial in chronically HBV-infected patients showing durable anti-HBV activity in the majority of treated patients, following a single, well tolerated dose.
Our Science
A New Therapeutic Approach to Treating Cancer and Infectious Diseases
The discovery and use of checkpoint inhibitors has revolutionized cancer treatment. But immunotherapies that can optimize CD8+ T cell responses have the potential to further improve clinical outcomes for many infectious diseases and cancers. Our iterative scientific approach is designed to produce novel, adaptable, and accessible disease-specific CD8+ T cell-based immunotherapies.
Our Pipeline
Virion Has a Series of Programs in Development
The experience from our recently completed Phase 1b trial of VRON-0200 for Chronic HBV, will help guide and accelerate other programs in our pipeline, including VRON-0300 for advanced solid tumors.